Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based life sciences company Pressure BioSciences has entered into a cooperative research and development agreement with the US Army Medical Research Institute of Infectious Diseases.
Subscribe to our email newsletter
Researchers at US Army Medical Research Institute of Infectious Diseases (USAMRIID) have recently shown that the use of the company’s patented pressure cycling technology (PCT) with patent-pending chemical reagents has resulted in the simultaneous decontamination and extraction of macromolecules (DNA, RNA, proteins, lipids) as well as small molecules from samples containing infectious pathogens.
The purpose of this cooperative research and development agreement (CRADA) is to adapt PCT into protocols for the development of medical countermeasures against dangerous pathogens that endanger the warfighter. The CRADA will allow scientists from Pressure BioSciences (PBI) and USAMRIID to combine resources, experiences, and expertise to help achieve this goal.
PBI will support the CRADA by offering USAMRIID the use of a Barocycler NEP3229 for a mutually agreed upon period of evaluation, by supplying consumable processing containers (Pulse Tubes) and kits to USAMRIID, and by the efforts of up to eight hours per week of technical support from PBI scientists. All of these items will be offered at no charge. Conversely, USAMRIID will support the CRADA through the technical support of its scientific staff available for both containment and non-containment work.
Richard Schumacher, founder, president, and CEO of PBI, said: “We believe that data generated under the CRADA could significantly accelerate and enhance current research studies involving infectious or dangerous agents. Such improvements could be of great importance to USAMRIID investigators, as well as to all scientists, whether military or in the public or private sector, who are working to develop more effective tools to counter bioterrorism.
“In addition, the knowledge gained from research performed under this CRADA may be of great importance to the many laboratories around the world working on the development of improved medical protections – including diagnostics, therapeutics, and vaccines – against infectious diseases not related to biological threat agents.”